Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that is in preclinical stage for use in the treatment of solid tumors. Vidac Pharma Holding Plc was founded in 2012 and is headquartered in London, the United Kingdom.
24 transactions — 0 buys and 24 sales reported by Vidac Pharma Holding Plc executives.
0 institutional funds report a position on T9G in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of T9G on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year